Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention and Treatment of Frostbite Infection
NCT06266494Phase 4Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dalbavancin in frostbite (3 arms), sponsored by University of Colorado Denver. Primary endpoints: Number of positive microbial wound cultures at Day 60, Number of gram positive cultures at Day 60 and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
dalbavancin
03
Conditions
frostbite
Beyond the preview
Go deeper on NCT06266494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266494.